World of DTC Marketing
AUGUST 23, 2022
Consumers would ask their doctor about an advertised prescription drug in a perfect world. In our REAL world, that isn’t the way it happens. Is there a disconnect between what DTC marketers think will happen and what happens with DTC? The research was straightforward. Ask current patients what drove them to get an Rx for a branded product (MS drug).
Pharmaceutical Technology
AUGUST 23, 2022
Gilead Sciences has obtained the European Commission (EC) marketing authorisation for Sunlenca (lenacapavir) injection and tablets to treat human immunodeficiency virus (HIV) infection. The twice-yearly treatment is indicated to be administered along with other antiretroviral(s) in adult patients with multi-drug resistant HIV infection who otherwise cannot have a suppressive anti-viral regimen.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 23, 2022
France’s BrainVectis, a subsidiary of Bayer’s Asklepios BioPharma (AskBio) unit, has been given the green light by regulators in France to start dosing patients with its gene therapy candidate for devastating neurodegenerative disorder Huntington’s disease. The phase 1/2 study is due to get underway before the end of the year and will test BrainVectis’ one-shot BV-101 gene therapy, which will be delivered using an adeno-associated virus (AAV) vector directly to areas of
Storyvine
AUGUST 23, 2022
It's a new day for non-profits and advocacy organizations. More than ever, your message needs to be heard. But with time and resources limited, what's the best way to do that? Video is the most popular form of content—78% of people watch online videos once a week—and it's especially effective for non-profits. With a real person telling a real story, combined with music and good editing, you can take your audience on an emotional journey that is very powerful.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmaVoice
AUGUST 23, 2022
PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant depression.
MedCity News
AUGUST 23, 2022
A new survey by the Business Group on Health found that 83% of employers said cancer is now the leading condition driving up healthcare costs, compared to 76% who said musculoskeletal conditions.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaVoice
AUGUST 23, 2022
Taren Grom, our editor-in-chief emeritus, explains how the coveted PharmaVoice 100 awards got its start and what makes it stand out in the industry.
pharmaphorum
AUGUST 23, 2022
Japan’s Takeda has secured its first regulatory approval – in Indonesia – for its dengue fever vaccine TAK-003, which has been tipped as a potential blockbuster product. Indonesia’s National Agency for Drug and Food Control (BPOM) has approved the vaccine as Qdenga to protect against the virus in people aged six to 45, on the back of data showing that it can cut dengue-related hospitalisations by 84%, with 61% protective efficacy against symptomatic illness seen up to three years aft
European Pharmaceutical Review
AUGUST 23, 2022
ON 11 JANUARY 2022, Regulation (EU) 2021/2282 on health technology assessment (HTA) came into force. 1 The regulation is the culmination of a long debate between European Union (EU) Member States and health sector stakeholders, triggered by joint actions such as European Network for Health Technology Assessment (EUnetHTA) and formalised through the European Commission (EC)’s proposal in January 2018. 2.
MedCity News
AUGUST 23, 2022
it is imperative that rural healthcare organizations take steps now to ensure that they provide access to a specialist, through traditional or digital solutions to meet these patient’s critical needs.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
AUGUST 23, 2022
A study of the causes of warning letters issued by the US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) between 2010 and 2020 revealed that poor current good manufacturing practice (cGMP) compliance and misbranding were the most common citations. Of the cGMP letters, three major types of violations – deficiencies in process validation, documentation practices (data integrity) and quality control – account
MedCity News
AUGUST 23, 2022
Bristol Myers Squibb’s drug R&D includes targeted protein degradation, an approach that can require proteins that don’t normally interact to find a way to stick together. BMS is turning to startup A-Alpha Bio to discover “molecular glues” that can accomplish the task.
European Pharmaceutical Review
AUGUST 23, 2022
FAKE MEDICINES are not a new problem, and pose a tremendous threat to patient safety and public health in society regardless of a country’s economic status. The prevalence of fake drugs is a continually growing problem worldwide. Fake drugs can be categorised as substandard, falsified, counterfeit and diverted drugs, and the World Health Organization (WHO) broadly defines a counterfeit medicine as “one which is deliberately and fraudulently mislabelled with respect to identity and/or source.” 1
MedCity News
AUGUST 23, 2022
The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
European Pharmaceutical Review
AUGUST 23, 2022
Researchers from the University of Arkansas (U of A) and two partner institutions have been awarded a $6 million grant by the US’s National Science Foundation (NSF) to develop purification membranes for future large-scale manufacturing of viral vectors and virus-like particles. According to the team, the successful development of commercial-grade purification membranes will increase access to new treatments for genetic and chronic diseases, especially for middle- and low-income people.
Copyright Clearance Center
AUGUST 23, 2022
The post Newest Improvements to CCC Marketplace Enhance Publisher-User Experience for Medical Communications Professionals appeared first on Copyright Clearance Center.
MedReps
AUGUST 23, 2022
It’s important to have good relationships with your clients. However, these relationships can often feel like a roller coaster ride because you are actively trying to sell your products to them. Whether they stop being interested in the medical products you represent or they are very busy and difficult to get ahold of, it’s up to you to maintain the relationship.
Medgadget
AUGUST 23, 2022
Oncoustics , a medtech company based in Ontario, Canada, developed the OnX Liver Assessment Solution, an AI-powered ultrasound-based diagnostic system for liver disease. At present, detecting liver disease is a challenge, potentially involving high-end imaging systems, specialists, and invasive biopsies. These challenges, and the related expense, can limit patient access to such testing for those with strong indications of liver disease.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
AUGUST 23, 2022
Pfizer and BioNTech have asked the FDA for emergency authorisation of an Omicron-targeted COVID-19 booster vaccine ahead of the planned autumn immunisation campaign in the US. The new version of their Comirnaty vaccine includes mRNA for the spike protein of the wild-type SARS-CoV-2 that first emerged in late 2019, as well as for the BA.4 and BA.5 subvariants of the now-dominant Omicron variant.
European Pharmaceutical Review
AUGUST 23, 2022
While combing for our typical insights into the pharmaceutical industry, we came across Scan of the Month and could not help but share their drug delivery device edition – a fascinating insight into the complexities of drug delivery devices many may take for granted. Using computerised tomography (CT) scanning, we can see beyond the consumer friendly design to the inner workings of two common drug delivery devices: the powder asthma inhaler and Mylan’s well-known EpiPen ®.
MedCity News
AUGUST 23, 2022
Actions ranging from data theft to ransomware cost the healthcare industry over $9.2 million on average for every breach. Guidelines for making computing environments that house and utilize sensitive protected healthcare data more secure are highlighted in a new whitepaper by Ventech.
European Pharmaceutical Review
AUGUST 23, 2022
A study led by Boston University School of Public Health (BUSPH) and the White River Junction Veterans Affairs Medical Center in Vermont has completed a rigorous analysis to compare the effectiveness of direct acting antivirals on improving symptoms of posttraumatic stress disorder (PTSD). . The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
pharmaphorum
AUGUST 23, 2022
Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals that value the US company at around $770 million. If completed, the deal will add two commercial products to Alcon’s range – glaucoma therapies Rocklatan (netarsudil/latanoprost) and Rhopressa (netarsudil) – as well as a pipeline of clinical and preclinical drug candidates currently headed by AR-15512, in phase 3 for dry eye disease.
Pharmacy Times
AUGUST 23, 2022
Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, said the company is in early stages of development for a combined mRNA vaccine for influenza, COVID-19, and RSV.
PharmaTimes
AUGUST 23, 2022
The marketing authorisation application is supported by results from a phase 3 trial for AML
Scott’s Directories
AUGUST 23, 2022
Data providers play the most decisive role in the success of marketing and sales campaigns. A competent data provider is likely to get better marketing outcomes and, thus, more sales. A good data provider provides companies with updated and relevant information, enabling marketers to develop an effective strategy targeting potential customers. High-value data, such as in the Ontario Physician Directory , saves time and effort.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmaTimes
AUGUST 23, 2022
Despite current treatments, the mortality rate for patients with invasive candidiasis remains high
Happy Living Medical Sales
AUGUST 23, 2022
The number of people living with physical disabilities continues to rise. There are millions of residents in the United States living with different physical disabilities, according to the Centers for Disease Control. Out of this number, a significant portion of residents use wheelchairs for daily mobility. Accessing buildings and public spaces can be challenging due to poor accessibility features.
PharmaKinnex
AUGUST 23, 2022
The Traditional Pharma Model Isn’t Working – It’s Time to Evolve! August 23, 2022. dstansberry@costellocreativegroup.com. The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. From new legislation to functional shifts in marketing and advertising, the pharma industry works hard every day to keep up with new regulatory requirements and the constantly evolving expectations of prescribers and patients.
Spotio
AUGUST 23, 2022
CRM mapping software can give your outside sales team a major competitive advantage. How efficient is your outside sales team? How many times have your sales reps walked into the office of a prospective lead, only to find that they’ve already spoken to another rep in your company? Or, what about the times your reps go all the way out to the boondocks to meet with a lead, and realize only once they step back into the office that they could’ve visited another lead just a few miles down the road?
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
243 
Let's personalize your content